News|Articles|November 16, 2026

More antigen on a cancer vaccine meant more tumor-fighting T cells in mice

Listen
0:00 / 0:00

Key Takeaways

  • Genetic modulation of phage coat-protein context and expression shifted antigen coverage from ~6.0% to ~70.4%, enabling controlled density changes while preserving particle size, length, and innate immune signaling.
  • Denser antigen display increased immune-cell uptake (~2.8-fold) and boosted antigen-specific CD8+ T cells (e.g., 7.4%→17.5% for model antigen; 1.1%→7.4% for Adpgk neoantigen).
SHOW MORE

A mouse study found that how much antigen sits on a vaccine’s surface, not just its size or shape, drives the T-cell response.

Loading more tumor antigen onto the surface of a virus-based cancer vaccine raised tumor-fighting T cells about seven times more in mice, according to a study published Oct. 29, 2026, in Advanced Healthcare Materials.

Personalized cancer vaccines are built around neoantigens, the mutated proteins that show up on a patient's tumor but not on healthy tissue. A vaccine has to carry two things: the neoantigen and something that wakes up the immune system. Both must reach the cells that show T cells what to attack. For years, researchers have studied how a particle's size, shape and charge affect that step, according to the study. How much antigen sits on the surface has drawn much less attention and that has become a gap that matters for health plans. These vaccines are in trials now, and design choices like this one affect how well they work and what they cost.

Shengnan Huang, a postdoctoral researcher at the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT), led the study along with her team of researchers. The team sought to find whether they could raise or lower the amount of antigen on purpose and whether that changed how strongly T cells responded. Funding came from the Koch Institute Frontier Research Program, the Marble Center for Cancer Nanomedicine and the U.S. Defense Advanced Research Projects Agency. The authors declared no conflicts of interest.

How the researchers changed the amount of antigen

The vaccine is built on M13, a bacteriophage, which is a virus that infects bacteria and does not infect people. Its genetic material sets off an immune alarm on its own, so the phage works as both a delivery vehicle and booster. The researchers attached antigen to the phage's most common surface protein. Then they changed how many copies appeared, using three genetic changes. They adjusted the electrical charge of the amino acids next to the antigen and moved where the antigen gene sat. A mutation that slowed antigen production was also added. Together, those moved antigen coverage from about 6.0% to about 70.4% of surface proteins, or roughly 36 to 420 copies per particle.

The team tested the vaccines in lab-grown immune cells first, then in female C57BL/6 mice 8 to 10 weeks old. Mice got two doses a week apart. Blood was checked on Day 14, and on Day 15 they were injected with tumor cells. Groups ran five to eight mice.

More antigen meant more T cells and slower tumor growth

The team started with a well-studied model antigen and raised coverage from about 6.0% to about 34.7% lifted antigen-specific CD8+ T cells in the blood from about 7.4% to about 17.5%. Immune cells also picked up the denser particles about 2.8 times more readily.

Researchers then tried the same approach with Adpgk, a neoantigen found in a mouse colorectal tumor line. Raising coverage from about 12.2% to about 53.2% pushed neoantigen-specific CD8+ T cells from about 1.1% to about 7.4%. Tumors grew more slowly, and the mice lived longer. Median survival was 38 days, compared with 28 days for the low-coverage vaccine and 25.5 days for mice that got no vaccine. That’s about 35% and 50% longer.

More antigen was not free as the version with the highest coverage cut phage yield sharply. The researchers added the slowing mutation to win most of that yield back while keeping coverage near 34.7%. That tradeoff is not a footnote for payers. Every patient needs a custom batch, so yield feeds straight into cost.

The study also ruled out an obvious alternative. The low- and high-coverage versions activated immune cells about equally and set off the same immune alarm. That points to the amount of antigen, not the strength of the booster, as the reason for the difference. One finding came with a caveat. PD-1, a marker on T cells, rose more than threefold on the neoantigen-specific cells. The authors read that as strong stimulation. They also note it can mean T cells are wearing out, which is why researchers are testing cancer vaccines alongside checkpoint inhibitors.

What the study can and cannot show

The design is the study's strongest feature. The phages compared carried the same genome, length and booster. The only real difference was how much antigen they displayed. That makes it reasonable to credit the results to antigen amount rather than something else. Coverage was also measured two different ways instead of estimated.

There are limitations as well. This is mouse research with no human data. The mice got their shots before tumors were implanted, so the study speaks to prevention in a lab model. It says nothing about treating a tumor that already exists, which is how cancer vaccines are used in practice. Groups were small, and each antigen was tested in one tumor model. The mechanism is unfinished too. Antigen presentation roughly doubled while the amount of antigen rose about 5.8-fold. The authors said that gap, and exactly how the denser particles get taken up, still needs work.

The authors do not claim the effect carries over to treatment. They write that a similar density effect in established tumors "requires further experimental validation." What they do recommend is that antigen density be treated as a design choice in its own right. They argue the principle should hold in other nanovaccine platforms too, as a general way to strengthen immune responses.


Related to this article